纳武利尤单抗注射液临床应用合理性与安全性分析

Rationality and Safety of Nivolumab Injection in Clinical Application

目的探讨纳武利尤单抗注射液临床应用的合理性与安全性。方法选取医院2021年11月至2022年11月收治的应用纳武利尤单抗注射液治疗的患者50例,观察其用药后的不良反应,并分析其用药合理性。结果50例患者共应用纳武利尤单抗注射液243例次,人均治疗4.86个周期;有39例(78.00%)患者的用药符合临床纳武利尤单抗注射液的适应证,药物应用剂量及方法均符合要求;发生药品不良反应20例(40.00%),其中6例(12.00%)为严重不良反应,占比最高(33.33%)的为免疫相关性肺炎。结论纳武利尤单抗注射液在该院的临床应用均合理,但药品不良反应发生率较高,临床需加强监护。

Objective To investigate the rationality and safety of nivolumab injection in clinical application.Methods Fifty patients treated with Nivolumab Injection in the hospital from November 2021 to November 2022 were selected,and their adverse reactions after medication were observed and the rationality of medication was analyzed.Results A total of 243 times were treated with Nivolumab Injection in 50 patients,with an average treatment period of 4.86 cycles per person.A total of 39 cases(78.00%)of patients had medication that met the indications for Nivolumab Injection,and the dosage and method of drug application met the requirements.Twenty cases(40.00%)of adverse drug reactions occurred,of which six cases(12.00%)were severe adverse reactions,with the highest proportion(33.33%)being immune related pneumonia.Conclusion The clinical application of Nivolumab Injection in this hospital is reasonable,but the incidence of adverse drug reactions is high,and clinical monitoring needs to be strengthened.